Medtrum's 300U Patch Pump with APGO Algorithm Eyes European Expansion

For biopharma companies and investors, Medtrum’s progress signals a potential shift in the automated insulin delivery landscape. A 300U patch pump with a proprietary AID algorithm entering a major European market under statutory reimbursement challenges established players and underscores the growing importance of device-drug combination platforms. The success of the APGO algorithm and Auto Meal Handling feature will be critical to differentiating Medtrum from well-funded incumbents.

At the Diabetes Kongress (DDG) 2026 in Berlin, Medtrum showcased its 300-unit tubeless insulin patch pump, advancing toward a commercial launch in Germany. The company, which operates globally in diabetes technology, announced that the higher-capacity device has been listed in Germany's statutory health insurance medical aids directory under a dedicated Hilfsmittelnummer. This administrative step is critical: it unlocks access to the nation's public reimbursement system, covering approximately 90% of the population, and signals a realistic pathway to market entry. For a medical device company, German reimbursement is a rigorous milestone that often serves as a bellwether for broader European adoption.

“

The 300U pump offers a 300-unit insulin reservoir, which Medtrum claims is 50% larger than the commonly used 200-unit patch pumps that dominate the tubeless market.

The 300U pump offers a 300-unit insulin reservoir, which Medtrum claims is 50% larger than the commonly used 200-unit patch pumps that dominate the tubeless market. For people with type 1 diabetes who require high daily insulin doses—due to insulin resistance, body mass, or lifestyle factors—larger reservoir capacity can mean fewer pump changes per week, potentially improving adherence and reducing therapy disruptions. Maintaining a discreet, tubeless form factor while expanding capacity addresses a specific patient subpopulation often underserved by current options. The pump belongs to the TouchCare Nano System, Medtrum's integrated platform that combines a tubeless patch pump, continuous glucose monitoring (CGM), the proprietary APGO automated insulin delivery (AID) algorithm, mobile app control, and remote data sharing. The system also features Auto Meal Handling, which allows users to announce a meal type rather than calculate exact carbohydrate counts—a simplification designed to lower the cognitive burden of diabetes management.

Medtrum's strategic focus on Germany is well-founded. The country is Europe's largest medical device market with an established reimbursement framework for diabetes technology, high clinical adoption of insulin pumps and CGM, and a population that includes a significant number of people with diabetes using advanced therapies. By securing a dedicated Hilfsmittelnummer, the 300U pump can be prescribed and reimbursed under statutory health insurance, removing a major financial barrier for patients and prescribers alike. CEO Scott Yang noted the company's intent to strengthen direct commercial operations, build partnerships, and generate clinical evidence—three pillars that suggest Medtrum aims to move beyond a distributor model to a direct presence in Europe.